Acetylcholine inhibits platelet activation and regulates hemostasis

Bennett, JA; Sk, Ture; Ra, Schmidt; Ma, Mastrangelo; Sj, Cameron; Le, Terry; Di, Yule; Cn, Morrell; Cj, Lowenstein

doi:10.1101/324319

Cited by 2 publications

(2 citation statements)

References 46 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 Furthermore, Bennett et al revealed that carbachol, an analog of acetylcholine, inhibits platelet activation through the attenuation of thrombin receptor. 44 In addition, AChEIs have been reported as having an anti-platelet effect in the endothelial cells, which play an essential role in ischemic stroke development. 36 These differences could be due to a different population being studied, seeing as we placed an emphasis on non-hypertensive AD patients.…”

Section: Discussionmentioning

confidence: 99%

Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non‐hypertensive Alzheimer's patients

Al-Hamed

Kouniaris

Tamimi

et al. 2021

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Introduction: Acetylcholinesterase inhibitors (AChEIs) are commonly used to treat mild to moderate cases of Alzheimer disease (AD). To the best of our knowledge, there has been no study estimating the risk of bleeding and cardiovascular events in patients with non-hypertensive AD. Therefore, this study aimed to estimate the association between AChEIs and the risk of bleeding and cardiovascular ischemic events in patients with non-hypertensive AD.Methods: A nested case-control study was conducted to estimate the risk of bleeding and ischemic events (angina, myocardial infarction [MI], and stroke) in patients with AD. This study was conducted using the UK Clinical Practice Research Datalink and Hospital Episode Statistics (HES) databases. The study cohort consisted of AD patients ≥65 years of age. The case groups included all AD subjects in the database who had a bleeding or ischemic event during the cohort follow-up. Four controls were selected for each case. Patients were classified as current users or past users based on a 60-day threshold of consuming the drug. Simple and multivariable conditional logistic regression analyses were used to calculate the adjusted odds ratio for bleeding events and cardiovascular events. Results:We identified 507 cases and selected 2028 controls for the bleeding event cohort and 555 cases and 2220 controls for the ischemic event cohort. The adjusted odds ratio (OR) (95% confidence interval [CI]) for the association of AChEI use was 0.93 (0.75 to 1.16) for bleeding events, 2.58 (1.01 to 6.59) for angina, and 1.89 (1.07 to 3.33) for MI. Past users of AChEIs were also at increased risk of stroke (1.51 [1.00 to 2.27]).Discussion: This is the first study assessing the risk of bleeding and cardiovascular events in patients with non-hypertensive AD. Our findings could be of great interest for clinicians and researchers working on AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non‐hypertensive Alzheimer's patients

Al-Hamed

Kouniaris

Tamimi

et al. 2021

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

show abstract

“…pulmonary embolisms. Acetylcholine is known to reduce platelet activation via α7 nicotinic acetylcholine receptors (α7nAChR) (8)(9)(10). Accumulating evidence suggests that stimulated platelets generate choline products, which activate the α7nAChR, resulting in a positive anti-inflammatory and anti-thrombotic impact.…”

Section: Introductionmentioning

confidence: 99%